DelMar Pharmaceuticals, Inc. announced the appointment of Mr. Saiid Zarrabian as interim Chief Executive Officer for a one year term, commencing on November 3, 2017. Jeffrey Bacha, cofounder of DelMar, will continue in his senior management role as President and in the newly created position of Chief Operating Officer (COO). Both Mr. Zarrabian and Mr. Bacha will continue to serve on the company's board of directors.

Mr. Saiid is currently serving as an advisor to Redline Capital Partners, S.A. In connection with Mr. Zarrabian's appointment as Interim Chief Executive Officer, Mr. Zarrabian will continue to serve as a director of the Company but will no longer serve on the Board's Audit Committee and Corporate Governance and Compensation Committee. Lynda Cranston will replace Mr. Zarrabian on the Company's Audit Committee and John Bell will replace Mr. Zarrabian on the Company's Corporate Governance and Compensation Committee.